Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent Mycoplasma pneumoniae and Epstein-Barr virus infections

BACKGROUND Mycoplasma pneumoniae(MP)frequently causes respiratory infections in children,whereas Epstein-Barr virus(EBV)typically presents subclinical manifestations in immunocompetent pediatric populations.The incidence of MP and EBV coinfections is often overlooked clinically,with the contributory role of EBV in pulmonary infections alongside MP remaining unclear.AIM To evaluate the serum concentrations of interleukin-2(IL-2)and interleukin-12(IL-12)in pediatric patients with MP pneumonia co-infected with EBV and assess their prognostic implications.METHODS We retrospectively analyzed clinical data from patients diagnosed with MP and EBV co-infection,isolated MP infection,and a control group of healthy children,spanning from January 1,2018 to December 31,2021.Serum IL-2 and IL-12 levels were quantified using enzyme-linked immunosorbent assay.Logistic regression was employed to identify factors influencing poor prognosis,while receiver operating characteristic(ROC)curves evaluated the prognostic utility of serum IL-2 and IL-12 levels in co-infected patients.RESULTS The co-infection group exhibited elevated serum IL-2 and C-reactive protein(CRP)levels compared to both the MP-only and control groups,with a reverse trend observed for IL-12(P<0.05).In the poor prognosis cohort,elevated CRP and IL-2 levels,alongside prolonged fever duration,contrasted with reduced IL-12 levels(P<0.05).Logistic regression identified elevated IL-2 as an independent risk factor and high IL-12 as a protective factor for adverse outcomes(P<0.05).ROC analysis indicated that the area under the curves for IL-2,IL-12,and their combination in predicting poor prognosis were 0.815,0.895,and 0.915,respectively.CONCLUSION Elevated serum IL-2 and diminished IL-12 levels in pediatric patients with MP and EBV co-infection correlate with poorer prognosis,with combined IL-2 and IL-12 levels offering enhanced predictive accuracy.

The in vitro Anti Hptocarcinoma Effects of Human Interleukin-12 from Transgenic Potato

[Objective]The aim was to examine the anti heptocarcinoma effects of human interleukin-12（hIL-12） from transgenic potatoes.[Method]Human heptocarcinoma cell line HepG22.2.15 was cocultured with human peripherial blood monocyte（PBMC）.Human IL-12 extracted from its transgenic patatoes was introduced to this coculture system.MTT method and laser confocal microscope were then employed to evaluate its survival rates and morphological changes of HepG22.2.15 cell line.[Result]The HepG22.2.15 survival rate of the plant produced hIL-12 treated group was significantly lower than that of the wild type control,while similar to that of commercial purified recombinant hIL-12 group.As indicated by AnnexinV/PI double staining laser confocal microscope,cocultured heptocarcinoma cells showed the typical early and final phase apoptotic morphological characteristics 48 hours after 2 × 10-4 mg/L potato secreted hIL-12 treatment.[Conclusion] These results demonstrated that Heptocarcinoma HepG22.2.15 cell growth could be actively inhibited by the transgenic potato expressed hIL-12 in vitro.

An effective vaccine against colon cancer in mice:Use of recombinant adenovirus interleukin-12 transduced dendritic cells

AIM： To investigate the effect of a vaccine with recombinant adenovirus interleukin-12 （AdVIL-12） transduced dendritic cells （DCs） against colon cancer in mice. METHODS： DCs and AdVIL-12 were incubated together at different time intervals and at different doses. Supernatant was collected and tested for IL-12 by enzyme-linked immunosorbent assay （ELISA）. In order to determine whether tumor cell lysate-pulsed （TP） AdVIL-12/DCs enhance therapeutic potential in the established tumor model, CT26 colon tumor cells were implanted subcutaneously （s.c.） in the midflank of naive BALB/c mice. Tumor-bearing mice were injected with a vaccination of CT26 TP AdVIL-12/DCs on d 3 and 10. As a protective colon tumor model, naive BALB/c mice were immunized s.c. in their abdomens with CT26 TP AdVIL-12/DCs twice at seven day intervals. After the immunization on d 7, the mice were challenged with a lethal dose of CT26 tumor cells and survival times were evaluated. Subsequently, cytotoxic T lymphocyte （CTL） activity and interferon gamma （IFNy） secretion was evaluated in the immunized mice, and assayed CTL ex vivo. RESULTS： Murine DCs were retrovirally transduced with AdVIL-12 efficiency, and the AdVIL-12 transduced DCs secreted a high level of IL-12 （AdVIL-12/DCs, 615.27 ± 42.3 pg/mL vs DCs, 46.32 ± 7.29 pg/mL, P 〈 0.05）. Vaccination with CT26 TP AdVIL-12/DCs could enhance anti-tumor immunity against CT26 colon tumor in murine therapeutic models （tumor volume on d 19：CT26 TP AdVIL-12/DCs 107 ± 42 mm^3 vs CT26 TP DCs 383± 65 mm^3, P 〈 0.05） and protective models. Moreover, the CT26 TP AdVIL-12/DC vaccination enhances tumor-specific CTL activity, producing high levels of IFN7 in immunized mice. Ex vivo primed T cells with AdVIL-12/DCs were able to induce more effective CTL activity than in primed T cells with CT26 TP/DCs （E：T = 100：1, 69.49% ± 6.11% specific lysis vs 37.44% ＋ 4.32% specific lysis, P 〈 0.05）.CONCLUSION： Vaccination with recombinant AdVIL-12 transduced DC pulsed tumor cell lysate enhance antitumor immunity specific to colon cancer in mice.

Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma

AIM: To explore the effect of intratumoral expressions of interleukin-12 (IL-12) and interleukin-18 (IL-18) on clinical features, angiogenesis and prognosis of gastric carcinoma. METHODS: The expressions of IL-12 and IL-18 from 50 samples of gastric cancer tissue were analyzed by immunohistochemistry, and microvessel density (MVD) was determined with microscopic imaging analysis system. RESULTS: The positive expression rates of IL-12 and IL-18 were 44% (22/50) and 26% (13/50), respectively. IL-12 was significantly associated with pathologic differentiation, depth of invasion, lymph node metastasis, distant metastasis, and TNM stage, and IL-18 was closely related to distant metastasis. Intratumoral IL-12 and IL-18 expressions were not statistically related to MVD scoring. IL-12-positive patients survived significantly longer than those with IL-12-negative tumors, but there was no significant difference between IL-18-positive patients and IL-18-negative ones. The multivariate analysis with Cox proportional hazard model revealed IL-12, MVD and T stage were independent prognostic factors. CONCLUSION: The positive expressions of IL-12 and IL-18 can play an important role in progression and metastasis of gastric cancer, and IL-12 might be an independent factor of poor prognosis in gastric carcinoma.

Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic inplication

Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gastrointestinal tract that share clinical and pathological characteristics. The most accredited hypothesis is that both CD and UC result from a deregulated mucosal immune response to normal constituents of the gut microflora. Evidence, however, indicates that the main pathological processes in these two diseases are distinct. In CD, the tissue- damaging inflammatory reaction is driven by activated type 1 helper T-cell (Th1), whereas a humoral response predominates in UC. Consistently, a marked accumulation of macrophages making interleukin (IL)-12, the major Th1-inducing factor, is seen in CD but not in UC mucosa. Preliminary studies also indicate that administration of a monoclonal antibody blocking the IL-12/p40 subunit can be useful to induce and maintain clinical remission in CD patients. Notably, the recently described IL-23 shares the p40 subunit with IL-12, raising the possibility that the clinical benefit of the anti-IL-12/p40 antibody in CD may also be due to the neutralization of IL-23 activity. This review summarizes the current information on the expression and functional role of IL-12 and IL- 12-associated signaling pathways both in patients with CD and experimental models of colitis, thus emphasizing major differences between IL-12 and IL-23 activity on the development of intestinal inflammation.

Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patients

AIM To evaluate the treatment effects of recombinant human interleukin-12(rh IL-12) on radiotherapy complications, such as severe myelosuppression or pancytopenia, the decline or imbalance of immune function, etc.METHODS The patients received high-dose and short-course precise radiotherapy, such as Cyber knife and image-guided radiotherapy(IGRT), which can cause myelosuppression or pancytopenia and immune function decline within a short time. One-hundred subjects were enrolled in the study, and 50 were randomized to a treatment group which used rh IL-12 and 50 were randomized to a control group which used symptomatic and supportive therapy after radiotherapy. The 50 subjects in the treatment group were further divided into five subgroups and intervenedwith rh IL-12 at a dose of 50, 100, 150, 200 or 250 ng/kg respectively. The dose-effect relationship was observed. RESULTS Rh IL-12 significantly attenuated the decrease of peripheral blood cells in the treatment group, and immune function was improved after treatment. Due to the different radiation doses, there was a fluctuation within 12 h after treatment but mostly showing an increasing trend. As to the clinical manifestations, 2 patients in the 250 ng/kg subgroup showed low fever after administration, 1 patient in the 200 ng/kg subgroup and 2 patients in the 250 ng/kg subgroup showed mild impairment of liver function during the observation period.CONCLUSION Rh IL-12 has effective therapeutic and protective effects on complications following radiotherapy, such as the decline of blood cells, myelosuppression and the decline or imbalance of immune function, which indicated good prospects for development and application.

Interleukin-12 as a Genetic Adjuvant Enhances Hepatitis C Virus NS3 DNA Vaccine Immunogenicity

Hepatitis C virus (HCV) chronic infection is a worldwide health problem, and numerous efforts have been invested to develop novel vaccines. An efficient vaccine requires broad immune response induction against viral proteins. To achieve this goal, we constructed a DNA vaccine expressing nonstructural 3 (NS3) gene (pcDNA3.1-HCV-NS3) and assessed the immune response in C57BL/6 mice. In this study, the NS3 gene was amplified with a nested-reverse transcriptase-polymerase chain reaction (RT-PCR) method using sera of HCV-infected patients with genotype 1a. The resulting NS3 gene was subcloned into a pcDNA3.1 eukaryotic expression vector, and gene expression was detected by western blot. The resultant DNA vaccine was co-administered with interleukin-12 (IL-12) as an adjuvant to female C57BL/6 mice. After the final immunizations, lymphocyte proliferation, cytotoxicity, and cytokine levels were assessed to measure immune responses. Our data suggest that co-administration of HCV NS3 DNA vaccine with IL-12 induces production of significant levels of both IL-4 and interferon (IFN)-γ (p<0.05). Cytotoxicity and lymphocyte proliferation responses of vaccinated mice were significantly increased compared to control (p<0.05). Collectively, our results demonstrated that co-administration of HCV NS3 and IL-12 displayed strong immunogenicity in a murine model.

Relationship of Serum Interleukin-18 and Interleukin-12 Levels with Clinicopathology in Renal Cell Carcinoma

Objective： To investigate the relationship between serum interleukin-18 and interleukin-12 levels and clinicopathology of renal cell carcinoma. Methods： Peripheral blood samples were obtained from 20 healthy volunteers and 60 patients with renal cell carcinoma before curative surgery. IL-12 and IL-18 levels were determined by enzyme-linked immunosorbent assay. Results： Mean serum IL-12 and IL-18 levels were significantly higher in patients with renal cell carcinoma compared with healthy volunteers （P〈0.05） and mean serum IL-12 and IL-18 levels increased in patients as the pathologic stage progressed. A positive correlation was observed between serum IL-12 and IL-18 levels （P〈0.05）. In patients with renal cell carcinoma, increasing serum IL-12 and IL-18 levels correlated with pathological stage and Fuhrman grade. Conclusion： Serum IL-12 and IL-18 might be useful tumor markers in patients with renal cell carcinoma.

Immune Killing Activity of Lymphocytes on Hela Cells Expressing Interleukin-12 In Vitro

The killing effects of lymphocytes on Hela cells expressing interleukin-12 （IL-12） in vitro were explored. By using gene transfection technique, full length IL-12 gene was transfected into Hela cells. The expression of IL-12 in Hela cells was detected quantitatively by ELISA; Changes in killing effects of lymphocytes on Hela cells expressing IL-12 were observed by MTT. It was found that Hela cells could express IL- 12 between 24 h and 72 h after transfection. Killing activity of lymphocytes on Hela cells expressing IL-12 was significantly enhanced. It was concluded by cell transfection technique, Hela cells could express 1L-12 and were more easily killed by lymphocytes.

Modulation of cellular and humoral immune responses to anHIV-1 DNA vaccine by interleukin-12 and interleukin-18 DNA immunization

Objective: To investigate the effect of interleukin-12 (IL-12) and interleukin-18 (IL-18)DNA immunization on immune response induced by HIV-1 DNA vaccine and to explore new strategies for therapeutic HIV DNA vaccine. Methods: The recombinant expression vector pCI-neoGAG was constructed by inserting HIV Gag gene into the eukaryotic expression vector pCI-neo. Balb/c mice were immunized with pCI-neoGAG alone or co-immunized with the DNA encoding for IL-12 or IL-18.Anti-HIV antibody and IFN-γ were tested by ELISA,and splenocytes were isolated for detecting antigen-specific lymphoproliferative responses and specific CTL response by MTT assay and LDH assay respectively. Results: The anti-HIV antibody titers of mice co-immunized with pCI-neoGAG and the DNA encoding for IL-12 or IL-18 were lower than that of mice immunized with pCI-neoGAG alone(P<0.01). In contrast, the IFN-γ level of mice co-immunized with pCI-neoGAG and the DNA encoding for IL-12 or IL-18 was higher than that of mice immunized with pCI-neoGAG alone (P<0.01).Furthermore, compared with mice injected with pCI-neoGAG alone, the specific CTL cytotoxity activity and antigen-specific lymphoproliferative responses of mice immunized with pCI-neoGAG and the DNA encoding for IL-12 or IL-18 were significantly enhanced respectively (P<0.01). Conclusion: The DNA encoding for IL-12 or IL-18 together with HIV DNA vaccine may enhance specific Th-1 responses and cellular immune response elicited in mice. Hence, the DNA encoding for IL-12 or IL-18 are promising immune adjuvants for HIV-1 DNA vaccine.

Influence of folic acid and vitamin B12 combined therapy on plasma Hcy, inflammatory factor levels and blood vessels endothelial function in patients with vascular dementia and type H hypertension

Objective:To investigate influence of folic acid and vitamin B12 combined therapy on plasma homocysteine (Hcy) level, blood vessels endothelial function and inflammatory factors in patients with vascular dementia and type H hypertension.Methods:100 cases of patients with vascular dementia and type H hypertension accorded with the inclusion criteria were selected as research objects. They were randomly divided as the control group and the therapeutic group, 50 cases each. For control group, Enalapril tablets were administered by mouth for treatment. For therapeutic group, folic acid and vitamin B12 treatment were provided on the basis of treatment for control group. Treatments were continued for 12 weeks. Plasma Hcy levels, inflammatory factors [(interleukin-6 (IL-6), interleukin-8 (IL-8) and hypersensitive C reaction protein (hs-CRP)], blood vessels endothelial function indexes variation in patients before and after treatment were observed and detected.Results:Plasma Hcy, IL-6, IL-8 and hs-CRP levels in two groups of patients after treatment were significantly decreased comparing with the same group before treatment, and the above index levels in therapeutic group after treatment were significantly lower than control group (P<0.05);For comparison of blood vessels endothelial function indexes in the patients, NO levels in two groups after treatment were increased in various degrees, and endothelin-1 (ET-1) were decreased. The differences between levels of the two indexes in therapeutic group before and after treatment were significant, and levels after treatment in therapeutic group were significantly better than in control group (P<0.05). While variations of the differences in control group before and after treatment were not significant (P>0.05);After treatment, diastolic pressure and systolic pressure in the two groups of patients were significantly improved comparing with before treatment (P<0.05). However, after treatment, the differences of levels between therapeutic group and control group were not significant (P>0.05). MMSE score in therapeutic group after treatment was significantly higher than before treatment, and significantly higher than in control group (P<0.05).Conclusions: Combined therapy of folic acid and vitamin B12 for treating vascular dementia with type H hypertension could effectively decrease plasma Hcy and inflammatory factor levels, and improve blood vessels endothelial function and dementia degree on patients. It has certain clinical value which deserves to be promoted.

Gα12 Regulates Interleukin-8 Expression after Epithelial Cell Injury

Acute kidney injury (AKI) is common in hospitalized patients and is strongly correlated with increased morbidity, mortality, and prolonged hospitalization. However, signals that determine whether injured tissues following AKI will repair or fibrose and lead to chronic kidney disease (CKD) are not well defined. Numerous cytokines are activated at various times after injury and recruit inflammatory cells. Interleukin-8 (IL-8) is upregulated following activation of Gα12 by H2O2, a reactive oxygen species (ROS). Herein, we study this occurrence in vitro and in vivo. IL-8 was measured by ELISA in Gα12-silenced (si-Gα12) and inducible QLα12 (constitutively active Gα12) Madin-Darby Canine Kidney (QLα12-MDCK) cell lines after H2O2/catalase cell injury. QLα12- and si-Gα12 MDCK cells showed time-, agonist- and Gα12-dependent increases in IL-8 mRNA and protein. Gα12-silenced MDCK cells demonstrated lower IL-8 expression and blunted IL-8 increases. In transgenic mice (QLα12γGTCre+, proximal tubule Qα12 expression) ischemia reperfusion injury led to significant upregulation of CXCL-1 (IL-8 homologue) at 48 hours that was not observed in Gα12 knockout mice. Macrophages in renal cells from these mice were imaged by immunofluorescent microscopy and QLα12γGTCre+ showed increased macrophage infiltration. We demonstrate that IL-8 is a critical link between H2O2 stimulated Gα12 and renal injury. Gα12 activation led to increased IL-8 expression, a potent mediator of inflammation after injury. Future studies targeting Gα12 for inhibition after injury may blunt the IL-8 response and allow for organ recovery.

不同剂量叶酸联合维生素B_(12)治疗老年高血压合并高同型半胱氨酸血症的临床效果

目的:分析不同剂量叶酸联合维生素B_(12)治疗老年高血压合并高同型半胱氨酸血症(HHcy)的应用效果.方法:选取2023年1—12月北京市延庆区妇幼保健院就诊的老年高血压合并HHcy患者67例作为研究对象,以随机数字表法分为观察1组(33例,小剂量叶酸联合维生素B_(12)治疗)和观察2组(34例,大剂量叶酸联合维生素B_(12)治疗).比较两组同型半胱氨酸(Hcy)及叶酸水平、收缩压(SBP)及舒张压(DBP)水平、不良反应发生率.结果:治疗前,两组患者Hcy及叶酸水平比较,差异无统计学意义(P>0.05);治疗后,两组患者Hcy水平均低于治疗前,叶酸水平均高于治疗前,观察2组优于观察1组,差异有统计学意义(P<0.05).治疗前,两组患者SBP及DBP水平比较,差异无统计学意义(P>0.05);治疗后,两组患者SBP及DBP水平均低于治疗前,观察2组低于观察1组,差异有统计学意义(P<0.05).两组均未出现过敏、肝损伤、肾损伤等不良反应.结论:叶酸联合维生素B_(12)在老年高血压合并HHcy治疗中的应用效果显著,其中采用0.8 mg叶酸的效果较佳,可有效改善Hcy及叶酸水平,稳定血压,且不良反应未增加,具有临床推广价值.

CA12-5联合月经血结核分枝杆菌检测对女性生殖系统结核诊断价值研究

目的探讨月经血结核分枝杆菌荧光定量PCR检测(fluorescent quantitative PCR,FQ-PCR)联合血清糖类抗原12-5(CA12-5)对女性生殖器结核(female genital tuberculosis,FGT)的诊断价值。方法回顾性分析2018年1月—2021年12月本院收治的160例输卵管性及不明原因不孕、复发性流产者,根据内镜下所见表现及病理检测结果,分析月经血结核分枝杆菌FQ-PCR及外周血清CA12-5含量(<35U/L)的检测效能,同时比较与血清结核分枝杆菌FQ-PCR阳性率及检测时长方面的优势。结果FQ-PCR及CA12-5联合检测对生殖器结核漏诊率为12.82%,低于月经血结核分枝杆菌FQ-PCR检测单独检测的64.10%与CA12-5的35.90%以及血清结核分枝杆菌FQ-PCR的7.18%,同时联合检测时间低于常规检查(培养及胸腔镜下检查)时间(均P<0.05)。结论无创月经血结核分枝杆菌FQ-PCR检测联合外周血清CA12-5在女性生殖器结核诊断方面较单一检测手段诊断效能高,漏诊率低,缩短检测时长,具有一定的临床实用价值。

慢性肝病患者T淋巴细胞亚群、IL-10和IL-12变化的意义

目的 :观察慢性肝病患者 T淋巴细胞亚群、IL- 10和 IL- 12与临床表现的关系。方法 :采用双抗体夹心 EL ISA法与抗体致敏的红细胞花环试验法 ,对 6 8例慢性乙肝病毒性肝病患者 T淋巴细胞亚群、IL- 10和 IL- 12进行平行测定。结果 :不同临床类型慢性肝病患者 CD4 +、CD4 + / CD8+明显低于对照组 ,而 CD8+明显高于对照组 ;慢性肝炎组 IL- 10、 IL- 12明显高于对照组 ;慢性 HBe Ag阳性肝炎患者 CD4 +、 CD4 + / CD8+及 IL- 12明显低于HBe Ag阴性患者 ,CD8+及 IL- 10明显高于 HBe Ag阴性患者。结论 :慢性乙肝病毒性肝病患者细胞免疫功能低下 ,免疫调节紊乱 ,IL- 10、 IL- 12水平及 T淋巴细胞亚群变化与患者 HBV携带状态即 HBV的复制活跃程度有关。

IL-2单独或联合IL-12增强G-CSF动员的人外周血单个核细胞抗肿瘤活性的研究

为了探讨IL 2单独或联合IL 12体外处理后 ,G CSF动员的人外周血单个核细胞 (G PBMC)抗肿瘤活性的变化 ,以NK细胞敏感的K5 6 2细胞和NK细胞抵抗的Raji细胞为靶细胞 ,采用乳酸脱氢酶 (LDH)释放法测定IL 2单独或联合IL 12诱导后G PBMC的抗肿瘤活性 ,同时采用流式细胞术分析诱导前后G PBMC的细胞表型。研究结果表明 :①未经处理的G PBMC的抗肿瘤活性很低 ;单独应用IL 2诱导 2 4小时即可以增强G PBMC的抗肿瘤活性 ,当诱导 72小时后G PBMC的抗肿瘤活性进一步增强 ;②IL 2联合IL 12诱导后的G PBMC抗肿瘤活性显著高于单用IL 2诱导后 ;③IL 2单独或联合IL 12诱导后G PBMC中CD3,CD8抗原表达增加 ,而CD5 6抗原表达仅在IL 2联合IL 12诱导 7天后增加。结论提示 :IL 2激活的G PBMC具有显著的抗肿瘤活性 ,联合IL 12诱导后其抗肿瘤活性进一步增强。

IL-12联合IL-2在伯氏疟原虫红内期感染中的免疫调节作用

目的探讨IL-12联合IL-2在抗P.berghei红内期感染中的免疫调节作用。方法BALB/c小鼠接种5×105个感染P.berghei的RBC,同时分别给予0.03μg/dIL-12、40U/dIL-2或IL-12联合IL-2处理,连续用药6d,观察小鼠原虫血症变化及存活时间。通过淋巴细胞增殖转化试验、T淋巴细胞亚群测定及NK细胞杀伤活性检测等方法,观察细胞免疫应答水平。结果IL-12联合IL-2处理组可较单独IL-12或单独IL-2及感染对照组显著推迟原虫血症达峰值的时间与明显延长小鼠的存活时间,IL-12或联合IL-2组小鼠在原虫血症达30%时开始死亡,而单独IL-2或感染对照组小鼠在原虫血症低于13%时已全部死亡。IL-12联合IL-2处理组脾淋巴细胞总数、CD4+与CD8+百分比、3H-TdR掺入量及NK细胞杀伤活性均较其它各处理组及感染对照组显著升高。结论IL-12与IL-2二者可协同促进脾淋巴细胞的增殖及增强NK细胞杀伤活性以诱导抗P.berghei红内期感染的免疫保护作用。

关节镜关节腔清理术后活血化瘀药物超声导入对膝骨性关节炎关节液中IL-17、CXCL12及MMP1表达的影响

目的研究关节镜关节腔清理术后活血化瘀药物超声导入对膝骨性关节炎关节液中白介素17(IL-17)、趋化因子12(CXCL12)及基质金属蛋白酶1(MMP1)表达的影响。方法选择医院2018年10月—2019年10月诊治的膝骨性关节炎患者106例作为研究对象,按照随机数字表法均分为两组、每组53例,对照组实施关节镜关节腔清理术治疗,观察组实施关节镜关节腔清理术后活血化瘀药物超声导入治疗。观察比较两组的临床优良率,膝关节恢复状态,关节液中生物标记物以及并发症发生情况,其中膝关节恢复状态指标为视觉模拟评分(VAS)、特种外科医院(HSS)膝关节评分、关节活动度,关节液中生物标记物为IL-17,CXCL12及MMP1。结果观察组、对照组的优良率分别为96.2%(51/53)、83.0%(44/53),观察组显著高于对照组(P<0.05)。治疗前两组VAS评分、HSS膝关节评分、关节活动度比较差异均无统计学意义(P>0.05),治疗后3个月两组VAS评分显著降低,HSS膝关节评分及关节活动度显著增加,并且观察组比对照组改善更为显著(P<0.05)。治疗前两组关节液中IL-17、CXCL12及MMP1水平比较差异均无统计学意义(P>0.05),治疗后3个月两组关节液中IL-17、CXCL12及MMP1水平均显著降低,并且观察组显著低于对照组(P<0.05)。观察组、对照组并发症发生率分别为5.7%(3/53)、9.4%(5/53),组间差异无统计学意义(P>0.05)。结论关节镜关节腔清理术后活血化瘀药物超声导入对膝骨性关节炎治疗效果显著,能够明显降低疼痛感、改善膝关节功能,还能够有效控制关节液中IL-17,CXCL12及MMP1表达,是安全有效的治疗方案。

无症状HBeAg阳性患者外周血单个核细胞培养液中IL-10、IL-12及γ-IFN检测水平的研究

探讨HBeAg阳性无症状乙肝病毒感染者免疫调控状况 ,采用外周血单个核细胞 (PBMC) ,体外刺激诱导培养 ,用ELISA法同时检测IL - 10、IL - 12及γ -IFN ,并以抗 -HBe阳性者、慢性肝炎及体检健康者作为对照。发现IL - 10不受HBeAg+ /抗 -HBe+的影响 ,经受刺激培养后其分泌明显高于正常对照组 ,在轻度ALT增高病人中亦呈分泌增强状态。γ -IFN在无症状HBeAg+组测定值明显较低 ;但在无症状抗 -HBe+、ALT及TBil异常组增高。IL -12检测水平在HBV感染各组均显著高于正常对照组 ,与血清转换及肝功异常无关。免疫负调控优势可发生于无症状HBeAg携带者。IL -

IL-12对炎症性肠病患者外周血和肠黏膜固有层淋巴细胞激活和炎症介质分泌的影响

目的:探讨IL-12对炎症性肠病患者外周血和肠黏膜固有层淋巴细胞激活和炎症介质分泌的影响。方法:收集并分离15例克罗恩病、21例溃疡性结肠炎和13例结肠镜检正常者(对照)外周血单个核细胞(PBMC)及肠黏膜固有层单个核细胞(LPMC),体外培养并用IL-12刺激,培养12h、24h、48h后,用流式细胞仪测PBMC或LPMCCD69表达情况;培养48h后,收集细胞培养上清液并用ELISA检测干扰素(IFN)-γ、IL-2和肿瘤坏死因子(TNF)-α的水平。结果:IL-12刺激后炎症性肠病患者外周血T细胞表达高水平的CD69。克罗恩病患者的PBMC和LPMCCD69表达水平及IFN-γ、IL-2和TNF-α分泌水平较溃疡性结肠炎和对照者明显增高(P<0.05)。结论:IL-12能直接刺激炎症性肠病患者外周血和肠黏膜固有层淋巴细胞激活,并产生大量促炎症介质。